Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
View through CrossRef
Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma.
Title: Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
Description:
Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options.
The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants.
Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC
Background and Aims:
Scirrhous HCC (SHCC) is one of the unique subtypes of HCC, characterized by abundant fibrous stroma in the tumor microenvironment. However, the mol...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract
Bevacizumab-containing protocols are all based upon the concomitant administration of the drugs given in a row. Bevacizumab is expected to induce a transien...
Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizum...
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Abstract
Introduction
Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor that can lead to severe complications and carries a risk of distant metastasi...
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma
Abstract
Background
Pulmonary sarcomatoid carcinoma is a rare tumor that is resistant to cytotoxic agents. This observational study aimed to evaluat...
Hepatocellular Carcinoma and Health‐Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies
Hepatocellular Carcinoma and Health‐Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies
Aim: Poor outcomes in advanced hepatocellular carcinoma (HCC) coupled with potential significant treatment side effects underpin a strong rationale to assess health‐related quality...